The whistleblower claims brought by a former sales representative for Abbott Laboratories alleging that the company illegally marketed its drug TriCor for off-label uses have survived a motion to dismiss in federal court.
The case falls in line with the Third Circuit’s shift toward a more relaxed pleading standard for off-label marketing claims under Federal Rule of Civil Procedure 9(b).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
